目的：主要是探索AD患者血漿中的tau與認知損害, CSF生物標誌物(Aβ和tau),腦萎縮，腦代謝有無關係。
簡介：患者來自2大研究：第一個就是ADNI——AD患者179例,MCI患者195例,認知正常對照189例；以及BioFINDER研究的AD、MCI、SCI患者人群。
結果：血漿tau升高與AD痴呆,CSF-tau升高,CSF-Aβ降低有微弱關係。ADNI隨訪研究提示有一定的預測價值。但是，與正常人群的重疊率太高，所以並不支持對於個體的疾病進展預測。
This study is the largest published on plasma tau,but it is not without limitations.
ADNI and BioFINDER samples were handled with different protocols and analyzed at different laboratories with different kit lots, which may have contributed to the varying results. Some ADNI participants had plasma tau below the lower limit of quantification of the assay (14 CNs, 11 patients with MCI, 10 patients with AD).
These measurements are uncertain but they were included because excluding them would have biased the data toward higher plasma tau (excluding them did not change the main results, data not shown). Another limitation is that we used only one plasma tau assay. It is possible that other assays capture tau fragments that are less sensitive to peripheral degradation and more likely to reflect AD pathology. A final limitation is that we did not covary for copathologies that may affect plasma tau levels
閱讀更多 徐俊主任醫師 的文章
